1121527-61-4 Usage
Description
Methyl N-ethylglycinate hydrochloride, also known as N-(2-Hydroxyethyl)-N-methylethanaminium chloride, is a quaternary ammonium compound with antimicrobial properties. It is used as a preservative and antimicrobial agent in various personal care and cosmetic products.
Used in Personal Care and Cosmetic Products:
Methyl N-ethylglycinate hydrochloride is used as a preservative and antimicrobial agent for its ability to inhibit the growth of microorganisms and prolong the shelf life of products.
Used in Skincare Products:
Methyl N-ethylglycinate hydrochloride is used as a safer and milder alternative to traditional preservatives, making it suitable for use in skincare products.
Used in Haircare Products:
Methyl N-ethylglycinate hydrochloride is used as a preservative and antimicrobial agent in haircare products to ensure their safety and longevity.
Check Digit Verification of cas no
The CAS Registry Mumber 1121527-61-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,2,1,5,2 and 7 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1121527-61:
(9*1)+(8*1)+(7*2)+(6*1)+(5*5)+(4*2)+(3*7)+(2*6)+(1*1)=104
104 % 10 = 4
So 1121527-61-4 is a valid CAS Registry Number.
1121527-61-4Relevant articles and documents
NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF
-
Paragraph 0239-0240, (2013/09/26)
The invention relates to indolizine derivatives of general formula (I), where A, B, m, W, n and R2 are as defined in claim 1, as well as to the method for preparing same and to the therapeutic use thereof.
PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS
-
Page/Page column 83, (2008/06/13)
CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
